uniQure announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 each in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate on December 7, 2022, 24 employees received 40,000 restricted stock units and options to purchase 26,000 ordinary shares of uniQure. Each option has an exercise price of $23.73 per share, the closing price per ordinary share as reported by Nasdaq on December 7, 2022. In the aggregate on October 31, 2022, 1 employee received 2,400 restricted stock units and options to purchase 1,500 ordinary shares of uniQure. Each option has an exercise price of $18.62 per share, the closing price per ordinary share as reported by Nasdaq on October 31, 2022. In the aggregate on September 27, 2022, 31 employees received 65,690 restricted stock units and options to purchase 55,970 ordinary shares of uniQure. Each option has an exercise price of $18.04 per share, the closing price per ordinary share as reported by Nasdaq on September 27, 2022.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on QURE:
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure announces positive CHMP opinion for etranacogene dezaparvovec
- uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
- uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
- uniQure reports on progress made in developing AMT-260